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Background: In rectal cancer, total mesorectal excision surgery combined with preoperative (chemo)radiotherapy
reduces local recurrence rates but does not improve overall patient survival, a result that may be due to the harmful side
effects and/or co-morbidity of preoperative treatment. New biomarkers are needed to facilitate identification of rectal
cancer patients at high risk for local recurrent disease. This would allow for preoperative (chemo)radiotherapy to be
restricted to high-risk patients, thereby reducing overtreatment and allowing personalized treatment protocols. We
analyzed genome-wide DNA copy number (CN) and allelic alterations in 112 tumors from preoperatively untreated rectal
cancer patients. Sixty-six patients with local and/or distant recurrent disease were compared to matched controls without
recurrence. Results were validated in a second cohort of tumors from 95 matched rectal cancer patients. Additionally, we
performed a meta-analysis that included 42 studies reporting on CN alterations in colorectal cancer and compared results
to our own data.
Results: The genomic profiles in our study were comparable to other rectal cancer studies. Results of the meta-analysis
supported the hypothesis that colon cancer and rectal cancer may be distinct disease entities. In our discovery patient
study cohort, allelic retention of chromosome 7 was significantly associated with local recurrent disease. Data from the
validation cohort were supportive, albeit not statistically significant, of this finding.
Conclusions: We showed that retention of heterozygosity on chromosome 7 may be associated with local recurrence in
rectal cancer. Further research is warranted to elucidate the mechanisms and effect of retention of chromosome 7 on the
development of local recurrent disease in rectal cancer.Background
The Dutch Total Mesorectal Excision (TME) trial [1]
changed standard treatment guidelines for rectal cancer
patients [2]. This international trial was designed to
provide a clinical assessment of whether additional pre-
operative short-term radiotherapy (pRT) could reduce
the number of local recurrences compared to TME sur-
gery alone. Based on the Dutch TME trial, patients with
tumor stage 2 (T2) were recommended to receive pRT
in addition to TME surgery [2]. The beneficial effect of
TME surgery combined with pRT on rectal cancer
local recurrence rates was subsequently confirmed in
a Dutch population-based study [3]. In addition to
pRT, preoperative concurrent chemoradiation treatment* Correspondence: T.van_Wezel@lumc.nl
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article, unless otherwise stated.(pCCRT) has been studied internationally and proposed
as a preoperative treatment for the reduction of local
recurrent disease related to rectal cancer. Reductions in
local recurrence achieved by pCCRT were similar to
those for pRT [4], and the postoperative complications
associated with pRT and pCCRT were also reported to
be comparable [5]. In 2013, an EURECCA consensus
was published which provided treatment recommenda-
tions for rectal cancer aimed at minimizing the differ-
ences in rectal cancer treatment regimes in Europe
[6,7]. Although both pRT and pCCRT are recom-
mended for specific TNM stages and introduction of
these approaches has reduced local recurrence rates
markedly, no difference in overall survival has yet been
achieved [2,4,8]. This lack of survival benefit is most
likely caused by the harmful side effects [9] and co-
morbidity of the preoperative treatment [2]. Recently, aed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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assess the survival benefit of pRT followed by full-dose
preoperative chemotherapy as an alternative for pCCRT
with and without postoperative chemotherapy [10].
Under current guidelines, preoperative treatment is of-
fered to a broad group of patients, although only around
10% of patients are actually at risk for development of a
local recurrence without preoperative treatment [2]. This
means that up to 90% of rectal cancer patients are un-
necessarily exposed to preoperative treatment [2]. This
undesirable situation calls for effective biomarkers
that allow for selection of those patients with a high
probability for development of a local recurrence after
surgery alone. Effective selection for pRT or pCCRT
treatment of only those rectal cancer patients with an
increased risk of recurrent local disease would reduce
overtreatment and allow for more personalized treat-
ment protocols.
Genetic profiling of copy number (CN) alterations in
individual chromosomes has previously been recognized
as an independent predictor for metastatic relapse of
early stage colorectal cancer [11]. The risk of develop-
ment of a local recurrence in rectal cancer can be de-
duced from the genetic aberrations found in the primary
tumor. In the current study, we were especially inter-
ested in the prognostic value of genomic alterations re-
lated to local recurrent disease in rectal cancer. The aim
of our study was therefore to identify CN alterations and
allelic imbalances that could predict risk of recurrence
in rectal cancer. Using a genome-wide CN analysis
approach, we analyzed tissues from 112 rectal cancer
patients enrolled in the TME trial. High-density SNP
arrays were used to assess CN alterations and allelic
(im)balances of genomic DNA (gDNA) segments [12,13].
As many studies have reported on CN alterations in
(colo)rectal cancer, we additionally performed a meta-
analysis of 42 studies that reported chromosomal CN
alterations (high frequency CN alterations at the level
of chromosome arms) and compared these to our current
findings. We hypothesized that the CN alterations and/or
aberrant allelic ratio patterns of certain gDNA segments
might be prognostic for a local recurrence in rectal cancer,
and might therefore identify those patients that would
benefit most from pRT or pCCRT.
Study cohort
Tumor and matching normal tissues from the Dutch TME
trial, which recruited rectal cancer patients in 118 European
centers and one Canadian center, were available for ana-
lysis. The trial design has been described previously [1]. We
selected patients (from the non-radiation treatment arm)
with clinically resected TNM stage I-III adenocarcinomas
of the rectum and a presentation of local and/or distant re-
current disease at follow-up. To exclude uncontrolled bias,patients with clinically resected TNM stage I-III adenocar-
cinomas of the rectum presenting without recurrent
disease were additionally selected to match those pre-
senting with recurrent disease. Individual control group
patients matched patients in the local recurrence group,
the distant recurrence group and the local & distant re-
currence group. For every patient within a recurrence
group (local, distant, or local & distant) a unique match
was therefore included. Matching criteria were TNM
stage (exact match), CRM involvement (exact match),
gender (exact match), and age at surgery (average differ-
ence of 2 years; range 0-7 years).
For the discovery phase, we selected tissues from 112
rectal cancer patients for whom fresh-frozen (FF) tumor
and normal matched tissues were available. These in-
cluded samples from patients with a recurrence (all
available local N = 10, distant N = 41, and all available
local & distant N = 15) and matched control patients
without a recurrence (N = 46). Three samples from the
discovery cohort were used for technical validation. For
validation of results, we selected tumor and normal
matched formalin-fixed paraffin-embedded (FFPE) tissue
from 95 patients. Patients presenting with a recurrence
(all available local, N = 12, distant, N = 24, and all avail-
able local & distant, N = 22) were matched to controls
(without any recurrence, N = 37). The discovery study
cohort (N = 112) and validation cohort (N = 95), which
did not overlap, are described in Table 1.
Consent
All samples were coded in accordance with national ethical
guidelines (“Code for Proper Secondary Use of Human
Tissue”, Dutch Federation of Medical Scientific Societies).
The use of these specimens was approved by the Medical
Ethical Committee of the Leiden University Medical
Center (LUMC). Patients were included in The Dutch
Total Mesorectal Excision (TME) trial after informed
consent was obtained [1].
DNA isolation
Genomic DNA (gDNA) from tumor and corresponding
normal tissue (FF or FFPE) was isolated, as described previ-
ously [14,15], following macrodissection or laser capture
microdissection (LCM). The DNA concentration was mea-
sured using the PicoGreen method (Invitrogen, Carlsbad,
CA, USA). If necessary, samples were concentrated using a
Speedvac (SC110A, ThermoFisher, Waltham, MA, USA) to
10 ng/μl or to a minimum of 15 μl.
CytoSNP arrays and analysis
Hybridization of gDNA to high resolution Illumina
Human CytoSNP12v2 arrays (Illumina, San Diego, CA,
USA), intensity data extraction and the first quality con-
trol steps were performed by ServiceXS (Leiden, the
Table 1 Summary of rectal cancer study cohorts
Discovery cohort (FF) Validation cohort (FFPE)
N = 112 Perc. N = 95 Perc.
Age at surgery
<50 14 13% 4 4%
50-75 72 64% 72 76%
≥75 26 23% 19 20%
Gender
Male 73 65% 57 60%
Female 39 35% 38 40%
TNM stage
Stage I 11 10% 7 7%
Stage II 24 21% 21 22%
Stage III 77 69% 67 71%
CRM involvement
No 82 73% 56 59%
Yes 30 27% 39 41%
Recurrence
No recurrence 46 41% 37 39%
Locala,b 10 9% 12 13%
Distantb 41 37% 24 25%
Local & Distanta,b 15 13% 22 23%
Abbreviations: aAll available patients with fresh frozen/FFPE tumor and
normal tissue specimens were included; bPatients with a recurrence were
matched to patients without a recurrence based on the matching criteria
TNM stage, CRM involvement, gender, and age at surgery; N = Number of
patients; Perc. = Percentage of total patients.
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the beadarraySNP package in R [13]. After normalization,
de-waving and automated segmentation analysis, we ob-
tained CN data and allelic ratio data for all arrays. Thresh-
olds for CN alterations after normalization were set at
0.92 for losses and 1.08 for gains, compared to the sample
mean. To designate the allelic ratio groups, DNA seg-
ments were divided per individual sample into three clas-
ses, retention of heterozygosity, imbalance and loss of
heterozygosity (LOH).
A globaltest (R package globaltest [16,17]) was per-
formed on both the continuous CN data and the overall
allelic ratio group data separately to determine overall
statistical differences between analysis groups, compar-
ing local recurrence group (L-group) versus control
group (C-group), distant recurrence group (D-group)
versus C-group and local & distant recurrence group
(LD-group) versus C-group. A significant global test on
the overall CN data or allelic ratio group data resulted in
a second global test on individual chromosome arms. If
significant, the smaller underlying segments underwent
a further global test to identify regions with significant
differences between the analysis groups. Multiple testingcorrection was performed using the Benjamin-Hochberg
(BH) method [18].
For allelic ratio group analyses of chromosome com-
binations, the overall chromosome status was classified
into balanced = 1, imbalanced = 2 and LOH = 3. Overall
chromosome status was defined as most abundant
allelic ratio group number on the chromosome. In the
chromosome combination analyses, the highest number
of overall chromosome status was used. Differences
between groups were assessed with Fisher’s exact test
for count data.
Survival analysis
Survival analysis was performed using the Cox proportional
hazards model (R-package survival). Survival data were
available for 12 years of follow-up. The mean follow-up
time of the discovery cohort and the validation cohort were
6.6 years (range 0.07-13.4 years) and 5.7 years (range 0.09-
13.6 years), respectively. Overall survival (OS) was defined
as the time from surgery until death by any cause. Disease
specific survival (DSS) was defined as the time from surgery
until death by rectal cancer. Local recurrence-free period
(LRFP) was defined as the time from surgery until the dis-
covery of a local recurrence. Distant recurrence-free period
(DRFP) was defined as the time from surgery until the
discovery of a distant recurrence. Multivariate models in-
cluded the predetermined clinically important covariates
TNM stage, age at surgery, gender and circumferential
margin involvement, irrespective of statistical significance.
Dynamic array and analysis
Based on the results from the discovery phase, reference
SNP (rs) identification numbers on chromosome 7 and 13
were extracted from the CytoSNP12 array. A search was
performed for validated ABI-Taqman SNP assays, based on
rs-numbers, in the SNP browser program (Applied Biosys-
tems, Foster City, CA, USA) and 48 SNPs were selected for
validation, with 16 on chromosome 7p, 16 on chromosome
7q and 16 on chromosome 13 (Additional file 1 S1). Selec-
tion was based on the highest percentage of heterozygosity
(at least 40%) as determined in the genotype call for normal
tissues (N = 112) in the discovery phase.
Taqman assays targeting the 48 selected SNPs were
tested using the 96.96 BioMark Dynamic Array for
quantitative Real-Time PCR (Fluidigm Corporation, San
Francisco, CA, USA). On the 96.96 BioMark dynamic
platform, Taqman SNP targets were assayed in duplicate
and samples were assayed in triplicate (technical valid-
ation) or duplicate (validation) using 14 cycles of Spe-
cific Target Amplification for each sample replicate
prior to the qPCR on the array. Assays were performed
by ServiceXS. Fluidigm Real-Time PCR analysis soft-
ware was used to extract cycle threshold (Ct) values,
while Fluidigm SNP Genotyping analysis software was
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for genotype calling. The linear derivative was used to
determine Ct threshold values per SNP assay. Samples
with a Ct >30 and missing values were set at Ct = 30.
The number of starting DNA molecules per reaction
chamber was computed using the following formula: #
DNA molecules = 2^(26-Ct). In the 96.96 BioMark dy-
namic assay, a Ct value of 26 corresponds to one DNA
molecule in the reaction chamber. Total sample mol-
ecule amount of the VIC (A-allele) and FAM (B-allele)
channels was used for sample normalization. The allelic
ratio, based on calculated amounts of DNA molecules
rather than intensity, can be calculated by dividing
the values for the VIC (A-allele) and FAM (B-allele)
channels.Validation of results
Based on quality control, samples with a mean log2
value lower than 4, and patients with non-matching
tumor and normal SNP genotypes, were excluded from
analyses. The Welch Two Sample T-test was used to as-
sess whether average allelic ratio values along chromo-
some 7p, chromosome 7q or chromosome 13 were
significantly different between the recurrence groups
and the control group. Survival analysis for validation of
results was performed as described above.Results and discussion
Description of frequently occurring copy number
alterations, and meta-analysis
We assessed CN alterations and chromosomal aberra-
tions in rectal cancers from the Dutch TME trial,
selected from the treatment arm that did not receive
pRT. To gain a broader perspective on the results of
our analysis of chromosomal CN alterations, we per-
formed a meta-analysis of previously published CN
studies. A PubMed search (performed on April 7,
2014), using the search criteria described in Additional
file 2 S2, yielded 325 published studies. Studies from
2005 to search date and additional studies (selected
from references of the selected articles published in
2005 or after) that described older CN alteration stud-
ies were assessed for eligibility, which required descrip-
tion of at least 6 tumors and detailed information on
CN alterations per chromosome arm. A total of 42
studies that reported data on CN alterations in rectal
cancer or colorectal cancer were included [11,19-59].
We combined results from these 42 studies (Table 2)
and one additional study published online just after our
Pubmed search (Table 2) and used the data to locate
high frequency CN alterations in colorectal cancer at
the level of chromosome arms (Figure 1A). CN alter-
ations reported in at least 40% of the studies for at least25% of the study cases were considered to be common
CN alterations with high frequencies.
Many included studies pooled colon and rectal
tumors and referred to them as colorectal cancer. How-
ever, evidence suggests that tumors arising from colon
and rectal tissues should be considered as distinct dis-
ease entities [60-62]. We therefore compared common
CN alterations with high frequencies in rectal versus
colon cancers. Twenty studies (including the present
study) specifically reported CN alterations in rectal car-
cinomas (Figure 1B). Frequent gains common in rectal
cancer included regions of chromosomes 7p (found in 75%
of the 20 rectal cancer studies, with a frequency >25%), 7q
(65%), 8q (100%), 13q (100%), 20p (70%) and 20q (85%).
Frequent losses common in rectal cancer were found on
chromosomes 1p (found in 55% of the 20 rectal cancer
studies, with a frequency >25%), 4q (50%), 5q (40%), 8p
(80%), 14q (40%), 15q (65%), 17p (95%), 18p (70%), 18q
(100%) and 22q (50%). Twelve studies reported CN alter-
ations specific to colon carcinomas (Figure 1C), with fre-
quent gains common in colon cancer on chromosomes 7p
(found in 67% of the 12 studies, with a frequency >25%),
7q (75%), 8q (75%), 13q (83%), 20p (42%) and 20q (92%).
Frequent losses common in colon cancer were found on
chromosomes 8p (found in 42% of the 12 studies, with a
frequency >25%), 17p (67%), 18p (67%) and 18q (92%). In
contrast to rectal cancer, frequent losses on chromosomes
1p, 4q, 5q, 14q, 15q and 22q were not observed in at least
40% of the colon studies. With the exception of loss at 4q,
these chromosome arms showed a difference of >20% be-
tween rectal cancer and colon cancer studies, indicating
that rectal cancers were associated with a higher frequency
of losses on these particular chromosome arms (Figure 1D).
In addition, the percentage of studies reporting frequent
losses on chromosomes 1q, 8p, 17p, and 21q, and the
percentage of studies reporting frequent gains on chro-
mosomes 8q and 20p, was higher in rectal cancer com-
pared to colon cancer. These differences may be explained,
in part, by the much higher percentage of microsatellite
unstable colon carcinomas in comparison to rectal car-
cinomas, because microsatellite instability reflects DNA
mismatch repair deficiency, in contrast to chromosomal
instability characterized by aneuploidy. Where possible,
microsatellite unstable tumors were omitted from our
comparisons, although many studies did not report micro-
satellite stability status.
In conclusion, frequent CN alterations common in
rectal cancer were located on chromosomes 1p, 4q, 5q,
7, 8, 13q, 14q, 15q, 17p, 18, 20 and 22q, while colon can-
cer showed a similar pattern but with a lower frequency
of gains at chromosomes 8q and 20p, a lower frequency
of losses at chromosomes 1q, 8p, 17p and 21q, and an
absence of frequent CN losses at chromosomes 1p, 4q,
5q, 14q, 15q and 22q.
Table 2 Colorectal cancer studies reporting on copy number alterations
Studies Origin of tissues Method Total CRC Rectum Colon TNM
stageFigure 1A # Figure 1B # Figure 1C #
1 Schlegel et al. 1995 Germany CGH yes 12 no (x) yes 12
2 Ried et al. 1996 Germany CGH yes 16 yes 6 yes 10 2/3/(4)
3 Meijer et al. 1998 the Netherlands CGH yes 14 yes 7 yes 7
4 Nakao et al. 1998 Japan CGH yes 9 no 0 yes 9 (1)/3
5 Paredes-Zaglul et al. 1998 USA CGH yes 9 yes 2 yes 7 (3)/4
6 Al-Mulla et al. 1999 UK CGH yes 12 no (x) no (x) 2/3
7 De Angelis et al. 1999 Norway CGH yes 45 no (x) no (x) 2/3/4
8 Georgiades et al. 1999 UK CGH yes 17 no (11) no (6) 1/2/3
9 Korn et al. 1999 USA CGH yes 6 no (0) yes 6 2/3/4
10 Aust et al. 2000 USA/Germany CGH yes 42 no (7) no (35) 1/2/3/4
11 Aragane et al. 2001 Japan CGH yes 30 no (x) no (x) 1/2/3/4
12 Chan et al. 2001 China/UK CGH yes 16 no (x) no (x) 2/3/4
13 De Angelis et al. 2001 Norway CGH yes 67 no (x) no (x) 1/2/3/4
14 Nakao et al. 2001 Japan CGH yes 35 no (13) no (22) 2/3/4
15 Rooney et al. 2001 USA CGH yes 29 no (4) no (25) 3
16 Hermsen et al. 2002 the Netherlands CGH yes 82 no (x) no (x) 1/(2)
17 Knösel et al. 2002 Germany CGH yes 15 no (x) no (x)
18 Alcock et al. 2003 UK CGH yes 17 yes 6 yes 11
19 Ghadimi et al. 2003 Germany CGH yes 50 yes 18 yes 32 1/2/3
20 He et al. 2003 China CGH yes 26 yes 14 yes 12 2/3/4
21 Leslie et al. 2003 UK CGH yes 50 no (21) no (29) 1/2/3
22 Bardi et al. 2004 Sweden/Denmark CGH yes 115 no (51) no (63) 1/2/3/4
23 Diep et al. 2004 Norway/Sweden CGH yes 10 no (x) no (x) (3)/4
24 Nakao et al. 2004 Spain aCGH yes 125 no (x) no (x) 1/2/3/4
25 Poeaim et al. 2005 Thailand CGH yes 40 no (10) no (30)
26 Tanami et al. 2005 Japan CGH yes 20 yes 9 yes 11 (2)/(3)/4
27 Al-Mulla et al. 2006 UK/Kuwait CGH yes 70 no (47) no (18) 1/2
28 Grade et al. 2006 Germany CGH yes 21 yes 21 no 0 2/3
29 Grade et al.a 2007 Germany CGH yes 32 no 0 yes 32 2/3
30 Lips et al. 2007 the Netherlands SNPa yes 77 yes 77 no 0 1/2/3
31 Xiao et al. 2007 China CGH yes 24 yes 9 yes 15
32 Lips et al. 2008 the Netherlands SNPa yes 32 yes 32 no 0 1/2/(3)
33 Grade et al.a 2009 Germany CGH yes 42 yes 42 no 0 1/2/3
34 Lagerstedt et al. 2010 Sweden aCGH yes 24 no (x) no (x) 1/2/3/4
35 Molinari et al. 2011 Italy aCGH yes 51 yes 51 no 0 1/2/3
36 Nakao et al. 2011 Japan aCGH yes 94 no (x) no (x) 1/2/3/4
37 Chen et al.b 2011/2012 USA aCGH yes 95 yes 95 no 0 2/3
38 Kodeda et al. 2012 Sweden aCGH yes 16 yes 16 no 0 1/2/3
39 Shi et al. 2012 China aCGH yes 8 yes 8 no 0
40 Liang et al. 2013 China aCGH yes 48 yes 48 no 0 2/3/4
41 Zhou et al. 2013 China aCGH yes 16 yes 16 no 0 2/3
42 Doyen et al. 2014 France/Germany SNPa yes 80 yes 80 no 0 (1/2/3)
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Table 2 Colorectal cancer studies reporting on copy number alterations (Continued)
43 This study 2014 the Netherlands SNPa yes 112 yes 112 no 0 1/2/3
Total 43 20 12
This table lists the published studies on CN alterations in rectal carcinomas used for comparisons with the present study (Nr. 43).
Abbreviations: CGH, comparative genome hybridization; aCGH, arrayCGH; SNPa, SNP array; aUnclear if there is overlap with study Nr. 29 (Grade et al. [29]), bChen
et al. published two papers based on the same patient cohort. Numbers in parentheses indicate the number of rectal or colon cancer patients included in the
study, but for which results could not be distinguished between groups.
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In order to identify CN alterations associated with a re-
currence in rectal cancer, we assessed CN alterations in
a series of non-preoperatively treated rectal cancers from
the Dutch TME trial. Rectal cancers with local and/or
distant recurrences were compared with matching con-
trol cases without recurrence. In terms of the location of
frequent gains, our study cohort was comparable to pre-
viously described rectal cancer cohorts (Figure 1B upperFigure 1 Frequent copy number alterations reported in colorectal cancer s
changes found in at least 25% of the cases in a study cohort. Since most s
frequency CN alterations were summarized. A-C. Percentage of high freque
CGH/SNP studies for colorectal (A; plotted from 20% to 100%), rectum (B; p
cancer. Top panel: Percentages of gains. Lower panel; percentages of losse
cases included in a particular study. X indicates the CN percentage from th
containing at least 15 SNPs. Open circles (O) represent other studies with r
plots or figures. For two studies [31,53], indicated by black diamonds (◊), p
the results of this study, were counted and plotted that reported on a chro
particular study. The percentages per chromosome arm for rectal studies a
indicated by open triangles (Δ∇). Triangles that point upwards (▲Δ) indica
downwards (▼∇) indicate the number of studies reporting on losses found
alteration to be common, with high frequency, when at least 40% of the spanel). In contrast, compared to previous studies we
detected a higher number of chromosome arms with fre-
quent losses (Figure 1B lower panel). This might be due
to our use of high-density arrays rather than CGH ar-
rays, and to the selection of previously studied CGH lo-
cations. Another explanation might be the larger sample
size of our study compared to most of the earlier studies,
as smaller studies are more prone to higher variance.
Additionally, our study differs from other studies due totudies. Frequent CN alterations were defined as copy number (CN)
tudies did not report low frequency CN alterations, only high
ncy CN alterations for each chromosome arm reported by different
lotted from 25% to 100%) or colon (C; plotted from 25% to 100%)
s. Symbol size (circles/diamonds/X’s) indicates the number of rectal
e current (SNP) study. Indicated losses are restricted to segments
eported percentages or percentages that could be estimated from
ercentages were not available. D. The percentage of studies, including
mosome arm showing CN alterations in ≥25% of the cases of that
re indicated with black-filled triangles (▲▼), while colon studies are
te the number of studies with reported gains and triangles that point
on the various chromosome arms. We considered a particular CN
tudies reported the CN alteration in at least 25% of the study’s cases.
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macrodissection. This could have influenced results by
reducing a potential effect in the analyses.
Genomic abnormalities and local recurrence
Continuous CN values and allelic ratio groups were ana-
lyzed in an effort to identify differentially affected gen-
omic regions in rectal cancer patients presenting with
and without local and/or distant recurrence. We in-
cluded all patients with a local recurrence for whom
fresh frozen tissue was available (N = 25). Fifteen of these
patients also presented with a distant recurrence. Add-
itionally, we included 41 patients presenting with only
distant recurrences. All patients with recurrent disease
were matched to control samples of patients who did
not present with a recurrence during follow-up (N = 46).
The frequency of gains (Additional file 3 S3A) and
losses (Additional file 3 S3B) along the length of each
chromosome was plotted for each analysis group (con-
trol group, local recurrence group, distant recurrence
group, and local & distant recurrence group). CN gains
were less frequently observed in the local recurrence
group compared to the other analysis groups, while CN
losses were more frequently observed in patients with a
local recurrence. However, CN alterations were not sig-
nificantly associated with (local) recurrent disease in our
study cohort. A similar pattern can be deduced from a
study by Diep et al. [49], with fewer CN gains and more
CN losses in local recurrences compared to independent
primary colorectal tumor samples. A lower frequency of
gains along chromosome 7 and higher frequency of
losses along chromosome 18q were especially associated
with local recurrence in both studies. A study by Kodeda
et al. [31], comparing locally recurrent and non-
recurrent rectal tumors, reported that both CN gains
and CN losses were less frequently observed in locally
recurrent tumors. Lower percentages of CN gains on
chromosomes 8q, 13q and 20q, and a lower frequency of
CN losses on chromosome 18q were observed in locally
recurrent tumors in both our study cohort and the
Kodeda cohort. In addition, we observed a lower fre-
quency of CN gains on chromosomes 9p, 16p, 17q, 19
and 22q in the locally recurrent tumors. In contrast to
the Kodeda study, we observed a higher frequency of
CN losses on chromosomes 1p and 5q in locally recur-
rent tumors, in addition to a higher frequency of losses
on chromosomes 3p, 9p and 15q. Overall, the results of
the Kodeda study were comparable with our study re-
garding the lower frequency of CN gains, but conflicting
on frequency of CN losses. This difference might be a
result of the higher number of small deletions identified
in our study due to our use of high-density SNP arrays
compared to the CGH arrays used by Kodeda et al.
However, despite these differences both the Kodedastudy [31] and our study share a common conclusion
that none of the above described CN alterations are
(statistically) significantly associated with local recurrent
disease.
An important feature of the SNP arrays used in our
study was that they allow assessment of allelic imbal-
ances, in addition to CN alterations. Using array data, al-
lelic ratio groups were analyzed in order to identify
genomic regions that showed allelic (im)balances associ-
ated with local and/or distant recurrence. The allelic
ratio of DNA segments was classified into three classes:
retention of heterozygosity, imbalance and LOH. In
contrast to CN alterations, allelic imbalance showed a
significant association with local recurrence, while no
association was found with distant recurrence or a
combination of both. Tumors from patients in the local
recurrence group showed overall statistically significant
differences in allelic ratios compared to the control sam-
ples (p < 0.005). Individual chromosome arms, and under-
lying segments and sub-segments, were then analyzed.
Several chromosome arms showed different allelic ratio
groups with (uncorrected) p-values <0.05 (Table 3A). In
all cases, the local recurrence group displayed fewer
allelic aberrations (allelic imbalance or LOH) than the
control group. Statistically significant sub-regions, with
p-values <0.05 after adjustment for multiple testing, were
identified on chromosome 7. These regions showed almost
no LOH (Additional file 4 S4). All tumors from patients
presenting with only a local recurrence showed retention
of heterozygosity and balanced alleles. In contrast, ap-
proximately 50 percent of control group cases showed
imbalanced alleles. The percentage of patients with reten-
tion, imbalanced alleles or LOH along the length of
chromosome 7 is shown in Figure 2. Balanced alleles
were more prominent in cases with only a local recur-
rence, indicating that retention on chromosome 7 might
be associated with the development of local recurrent
disease. Frequent gains of chromosome 7, with or without
allelic imbalances, were most often identified, and true
LOH was almost non-existent in our study cohort. This
suggests that heterozygosity of chromosome 7 is import-
ant for rectal cancer tumorigenesis and warrants further
studies on the role of chromosome 7 retention in local
recurrences of rectal cancer.
The use of heterozygous SNPs to determine allelic ra-
tios of normal and tumor samples identified statistically
significant differences on chromosome 7 between pa-
tients presenting with and without only local recurrent
disease.
Validation
A validation of the association of chromosome 7 reten-
tion with local recurrence was performed using the
96.96 BioMark dynamic platform. A technical validation
Table 3 Differential allelic ratio groups between local recurrence and control
A) Local recurrence group Control group
Chr. p-value BH Retention Imbalance LOH Retention Imbalance LOH
1q 0.05 0.17 89% 11% 0% 45% 53% 2%
4q 0.05 0.17 78% 22% 0% 47% 22% 31%
7p 0.0005 0.015 100% 0% 0% 36% 62% 2%
7q 0.0007 0.015 100% 0% 0% 9% 13% 78%
10p 0.04 0.17 89% 11% 0% 53% 45% 2%
11p 0.04 0.17 89% 11% 0% 49% 42% 9%
13q 0.04 0.17 78% 11% 11% 27% 60% 13%
14q 0.017 0.17 78% 22% 0% 40% 22% 38%
15q 0.03 0.17 78% 22% 0% 29% 29% 42%
16q 0.06 0.18 89% 11% 0% 53% 36% 11%
17p 0.03 0.17 22% 33% 44% 9% 13% 78%
18q 0.05 0.17 11% 22% 67% 9% 13% 78%
22q 0.04 0.17 78% 11% 11% 33% 31% 36%
B) Local recurrence group Control group
Chr. p-value Retention Imbalance LOH Retention Imbalance LOH
7 0.0025 9 0 0 19 25 1
13 0.0062 7 1 1 12 27 6
7 + 13 <0.0002 7 1 1 5 33 7
A) For comparison of the local recurrence group and control group, chromosome arms are listed that showed significant allelic ratio groups with p-values <0.05
and adjusted p-values <0.2.
Abbreviations: Chr, chromosome; B, p-value after using the Benjamin-Hochberg method for multiple testing correction.
B) For chromosome 7, chromosome 13 and in combination, the numbers of patients within each ‘overall chromosome status’ group - defined as the most
abundant allelic ratio group on the chromosome - are shown for both the local recurrence group (L) and the control group (C). Fisher’s exact test for count data
was used to determine the statistical differences between analysis groups L and C.
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ation of our results (Additional file 5 S5). We selected all
(remaining) patients with a local recurrence for whom
FFPE tissue was available (N = 34). Of these patients, 22
also presented with a distant recurrence. Additionally,
we included 24 patients presenting with only distant
recurrences. All patients with recurrent disease were
matched to control patient samples without recurrence
in follow-up (N = 37).
Differences in frequency of allelic (im)balances of
specific SNPs on chromosome 7 were assessed in FFPE
tissues of rectal cancer patients presenting with and
without local and/or distant recurrence. Based on the
results from the discovery phase, we selected 32 SNPs
located on chromosome 7p (N = 16) and chromosome
7q (N = 16) (Additional file 1 S1). As a high percentage
of patients presenting with only a local recurrence also
showed retention on chromosome 13 (Figure 2), an add-
itional set of 16 SNPs was selected on this chromosome
to potentially increase discriminative power. SNPs on
both chromosome 13 and chromosome 7 were therefore
included to enhance differences between analysis groups.
During the discovery phase, the overall chromosome sta-
tus of combined chromosomes 7 and 13 was significantlydifferent in patients in the local recurrence group com-
pared to the control group (Fisher’s exact test for count
data, p-value < 0.0002; Table 3B). Balanced alleles were
more prominent in cases with a local recurrence, indicat-
ing that retention on chromosome 7, and to a lesser extent
on chromosome 13, might be associated with the develop-
ment of a local recurrence.
Using the technically validated dynamic array approach,
differences between the local recurrence group and the
control group showed a trend towards significance on
chromosome 7p (p-value = 0.07). Retention of heterozy-
gosity was more frequently observed in tumors with local
recurrence compared to control group tumors, which is in
accordance with findings in the discovery phase (Figure 3).
The telomeric region of chromosome 7p showed allelic
imbalance or LOH in consistently lower percentages of
patients in the local recurrence group compared to the
control group. For the centromeric region, the same pat-
tern was observed for both the local recurrence group and
for the local & distant recurrence group. Chromosome 13
retention results could not be reproduced.
In brief, validation cohort data were not conclusive
but do support the notion that retention of heterozy-
gosity on the telomeric and centromeric regions of
Figure 2 Distribution of the allelic ratio groups on chromosome 7 and 13 in the discovery phase. Legend: - - - (Red broken line) = local recurrence
group, - - - (Blue broken line)= distant recurrence group, - - - (Cyan broken line) = local and distant recurrence group, - - - = control group. The
percentage of patients, divided into four groups according their recurrence status, with tumors that contain balanced alleles (A), imbalanced alleles
(B), and LOH (C), spread along chromosomes 7 and 13.
Figure 3 Frequency of allelic imbalance or LOH at validated
loci. The percentage of patients with loss (imbalanced alleles or
LOH), spread along chromosomes 7 and 13. All SNPs below the
orange line (— Orange Line) represent SNPs that presented
with lower percentages of patients in only the L or LD groups.
X-axis = from left to right, locations of SNPs along the
chromosome (arms) Y-axis = the percentage of patients with
imbalanced alleles or LOH (0 = > 0%, 1 = > 100%) ● = C group,
(Red circle) = D group, (Green circle) = L group, (Blue circle) = LD
group. A) Location on chromosome 7p (telomeric region)
where the L group in particular showed a lower percentage of
patients with imbalanced alleles or LOH compared to the other
groups. B) Location on chromosome 7p (centromeric region)
where both the L group as well as the LD group showed a
lower percentage of patients with imbalanced alleles or LOH
compared to the other groups.
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in rectal cancer.
Prognostic value of CN alterations and allelic aberrations
The clinical prognostic value of continuous CN profiles
and allelic ratio group profiles was assessed in the dis-
covery cohort using the Cox proportional hazards
model. Multivariate analyses showed a trend in associ-
ation of chromosome 7p with local recurrence (LRFP),
but no associations with any other clinical outcome in
our cohort of rectal cancer patients (Additional file 6
S6). In our discovery study cohort, allelic imbalance was
associated with death by rectal cancer and local recur-
rent disease, with the allelic imbalance at chromosome
7p being chiefly responsible for the prognostic effect for
local recurrent disease (Additional file 6 S6). These re-
sults could not be confirmed with the 48 selected SNPs
using the dynamic array (data not shown), and this out-
come is reflected in the absence of literature describing
associations between CN alterations or allelic ratio pro-
files and patient survival in rectal cancer patients.
Only one study specifically dedicated to rectal cancer
patients reported an association of CN alterations with
patient survival or recurrent disease [63]. The study by
Doyen et al. [63] showed (in multivariate analysis) an as-
sociation of loss at chromosome 8p with worse cancer
specific survival (CSS) and the occurrence of meta-
chronous distant metastases (DRFP). Unfortunately, the
Goossens-Beumer et al. BMC Genomics  (2015) 16:438 Page 10 of 12covariates included in the multivariate analysis where not
reported. Four previously published colorectal cancer
studies reported associations of CN alterations with pa-
tient survival or recurrent disease [11,45,48,64]. A study
by De Angelis et al. [48] showed worse overall survival for
patients with losses at chromosomes 1p and 8p in multi-
variate analyses. Bardi et al. [45] observed a significant
association between loss at chromosome 4 and worse
disease-free survival in univariate analyses. In multivariate
analysis, loss of chromosome 18 was reported to be associ-
ated with worse overall survival. Al-Mulla et al. [11] re-
ported that loss at chromosomes 4p and 5q was associated
with worse disease-free survival in early stage colorectal
cancers in multivariate analyses. Allelic imbalance at
chromosome 8p was reported by Halling et al. [64] and
associated with overall survival (OS) and time to recur-
rence (DRFP) in multivariate analysis. Association be-
tween allelic imbalance or loss at chromosome 8p and
worse clinical outcome was described in three independ-
ent articles. However, only one was dedicated specifically
to rectal cancer, and our study could not validate the re-
sults. The differences in results between these studies and
our own data might be due to differences in tumor loca-
tions, as we focused on rectal cancer patients alone,
whereas four out of five earlier studies included both
colon and rectal cancer patients. Additionally, our use of
laser capture microdissection along with macrodissection
in order to reduce the potential effect of tumor micro-
environment on the analyses, and thereby reduction of
intratumoral heterogeneity of the rectal tumors, might
provide a truer picture of the association between CN
alterations and clinical outcome.
Allelic aberrations and LOH in colorectal cancer have
been widely investigated, and loss of 18q and 17p are
seen as prognostic markers for clinical outcomes in
colorectal cancer (reviewed in [65]). To the best of our
knowledge, no study has previously focused specifically
on rectal cancers. A study by Choi et al. [66] showed
that higher levels of LOH were significantly associated
with tumor location specifically in the rec and the distal
portion of the colon. This finding indicates that rectal
and colon tumors should be considered distinct disease
entities in relation to allelic alterations and LOH in par-
ticular. Prognostic indicators identified in studies of
colorectal cancer patients cannot be adequately com-
pared with (our) survival data on rectal cancer patients.
Conclusion
Implications for clinical use
Rectal cancer is associated with a high rate of local
recurrence, in contrast to colon cancer. The location of
the rectum, fixed in the smaller pelvis, provides oppor-
tunities for pRT or pCCRT treatment. Although intro-
duction of pRT and pCCRT led to markedly reducedlocal recurrence rates (from 11% to 5% for pRT [2]), no
difference in overall survival was observed [2,4,8]. This
suggests that the majority of rectal cancer patients (over
90%) are currently receiving unnecessary preoperative
treatment to reduce the local recurrence risk, when in
fact this risk is only relevant for less than 10% of all pa-
tients. Identification of patients who are likely to show
local recurrent disease could guide decision-making for
the preoperative treatment of rectal cancer patients.
Validation data from the present study on allelic ratios
of chromosome 7 are supportive (but not conclusive) of
our initial finding that retention of heterozygosity on
chromosome 7 is associated with local recurrent disease.
While these data do not yet provide sufficient grounds
for development of a clinically useful platform based on
these observations, further research is warranted to elu-
cidate underlying mechanisms. Chromosome 7 harbors
many interesting genes, including druggable targets such
as the oncogenes EGFR, BRAF and MET, but at present
their relation to the retention of chromosome 7 and the
development of local recurrent disease in rectal cancer is
unclear. Comparison of data on CN alterations and
allelic imbalance from our rectal cancer cohort with
previously published studies provided support for the
hypothesis that colon cancer and rectal cancer may be
distinct disease entities, and thus may require stratifi-
cation in (survival) analyses accordingly.
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